Immunotherapy firm, Genelux Corporation, has entered a licensing agreement with ELIAS Animal Health for its V-VET1, a vaccinia viral strain. The clinical-stage product is intended to replicate in cancer cells causing the death of cancer cells. ELIAS specializes in veterinary cancer care that uses T-cell immunotherapy.
Cancer is the top reason dogs die in the US, and treatment options often do not prolog life for a significant length of time. The therapy being investigated in a Phase 1 study will be given to dogs with varied types of cancer, including anal glad carcinoma, mast cell tumors, osteosarcoma, soft tissue sarcoma, and T-cell lymphoma. During the study, a maximum tolerated dose was not found as dogs were able to handle the dosages well, and disease control and responses were found.
"We are excited to be working with ELIAS Animal Health to advance V-VET1 for the treatment of dogs and other non-human animals with various cancers," said Thomas Zindrick, president and chief executive officer of Genelux. "Unfortunately, few veterinary-only drugs currently exist to treat companion animals with cancer. ELIAS is doing tremendous work to advance novel treatments for animal health, including cutting-edge adoptive T cell therapy combined with surgery and radiotherapy, and we are proud to partner with them."
The agreement between ELIAS and Genelux will provide the latter with funding at the outset and at predetermined sales and development milestones. After reaching the market, Genelux will receive royalties on sales of its product.